Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis

Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis

Background: Although elevation of HDL-C levels by pharmaceutical drugs have no benefit of cardiovascular endpoint, the effect of high-density lipoprotein/apolipoprotein A1 (HDL/apoA-1) replacement therapy on atherosclerosis is controversial. The current meta-analysis analyzed the effects of HDL/apoA...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Ayiguli Abudukeremu, Canxia Huang, Hongwei Li, Runlu Sun, Xiao Liu, Xiaoying Wu, Xiangkun Xie, Jingjing Huang, Jie Zhang, Jinlan Bao, Yuling Zhang
Formato:	Artigo
Idioma:	English
Publicado em:	Frontiers Media S.A. 2021-08-01
Colecção:	Frontiers in Cardiovascular Medicine
Assuntos:	lipoproteins HDL apolipoprotein A-I mimetic atherosclerosis
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fcvm.2021.700233/full

Registos relacionados

Proteomic and functional analysis of HDL subclasses in humans and rats: a proof-of-concept study
Por: Canxia Huang, et al.
Publicado em: (2023-06-01)

A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids
Por: Mohamad Navab, et al.
Publicado em: (2009-08-01)

Association of human apolipoprotein E with lipoproteins secreted by transfected McA RH7777 cells
Por: Catherine A. Reardon, et al.
Publicado em: (1998-07-01)

Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide <span style="font-variant: small-caps">d</span>-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice
Por: Andrea Rivas-Urbina, et al.
Publicado em: (2020-05-01)

Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research
Por: Karin Kornmueller, et al.
Publicado em: (2019-08-01)

Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits
Por: Brian J. Van Lenten, et al.
Publicado em: (2007-11-01)

A Systematic Review of Apolipoprotein A-I Mimetic Peptides for Atherosclerosis Therapy via Activation of Reverse Cholesterol Transport Pathway
Por: Aiman Asaduddin, et al.
Publicado em: (2022-11-01)

Apolipoprotein Mimetic Peptides: A New Approach for the Treatment of Asthma
Por: Xianglan eYao, et al.
Publicado em: (2012-03-01)

Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization
Por: Jie Tang, et al.
Publicado em: (2017-01-01)

High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease
Por: Elizabeth M. Gordon, et al.
Publicado em: (2016-09-01)

Apolipoprotein A1 and high-density lipoprotein limit low-density lipoprotein transcytosis by binding SR-B1
Por: Karen Y.Y. Fung, et al.
Publicado em: (2024-04-01)

Pro- or anti-inflammatory role of apolipoprotein A-1 in high-density lipoproteins?
Por: Nicolas Vuilleumier, et al.
Publicado em: (2013-05-01)

Cholesterol–sphingomyelin interaction in membrane and apolipoprotein-mediated cellular cholesterol efflux
Por: Jin-ichi Ito, et al.
Publicado em: (2000-06-01)

D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet
Por: Georgette M. Buga, et al.
Publicado em: (2008-01-01)

Characterization and quantification of serum lipoprotein subfractions by capillary isotachophoresis: relationships with lipid, apolipoprotein, and lipoprotein levels
Por: Alexandra Schlenck, et al.
Publicado em: (1999-11-01)

Apolipoprotein E3-mediated cellular uptake of reconstituted high-density lipoprotein bearing core 3, 10, or 17 nm hydrophobic gold nanoparticles
Por: Chuang ST, et al.
Publicado em: (2017-11-01)

Characteristics of lipid metabolism including serum apolipoprotein M levels in patients with primary nephrotic syndrome
Por: Lagu He, et al.
Publicado em: (2017-09-01)

The Differential Effects of HDL Subpopulations on Lipoprotein Lipase (LPL)-Mediated VLDL Catabolism
Por: Ewa Wieczorek, et al.
Publicado em: (2021-12-01)

Admission levels of high-density lipoprotein and apolipoprotein A-1 are associated with the neurologic outcome in patients with out-of-hospital cardiac arrest
Por: Yong Soo Son, et al.
Publicado em: (2017-12-01)

Preparative free-solution isotachophoresis for separation of human plasma lipoproteins: apolipoprotein and lipid composition of HDL subfractions
Por: Alfred Böttcher, et al.
Publicado em: (2000-06-01)

High-density lipoprotein, and apolipoprotein A-I: a regulatory role and novel therapeutic strategies for the treatment atherosclerosis
Por: L. M. Polyakov, et al.
Publicado em: (2013-03-01)

Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis
Por: Monique F. M. Santana, et al.
Publicado em: (2020-09-01)

Reconfiguring Nature’s Cholesterol Accepting Lipoproteins as Nanoparticle Platforms for Transport and Delivery of Therapeutic and Imaging Agents
Por: Skylar T. Chuang, et al.
Publicado em: (2020-05-01)

Research progress on the relationship between high density lipoprotein and bronchial asthma
Por: MAO Wenjie, HUANG Zhiying
Publicado em: (2024-05-01)

Regulation of human apolipoprotein A-I gene expression by equine estrogens
Por: Xia Zhang, et al.
Publicado em: (2001-11-01)

Evaluating the relation between serum apolipoprotein B (apo B), apolipoprotein A (apo A) and apo B/apo A ratio with diabetic retinopathy in a sample of type 2 Egyptian diabetic patient
Por: Salwa Seddik Hosny, et al.
Publicado em: (2023-08-01)

Peptide model of a highly conserved, N-terminal domain of apolipoprotein E is able to modulate lipoprotein binding to a member of the class A scavenger receptor family
Por: Samuel R. Dominguez, et al.
Publicado em: (1999-04-01)

Apolipoprotein E-containing HDL decreases caspase-dependent apoptosis of memory regulatory T lymphocytes
Por: Laura Atehortua, et al.
Publicado em: (2023-09-01)

Proatherogenic Sialidases and Desialylated Lipoproteins: 35 Years of Research and Current State from Bench to Bedside
Por: Alexandre Mezentsev, et al.
Publicado em: (2021-05-01)

Volumetric determination of apolipoprotein stoichiometry of circulating HDL subspecies1[S]
Por: Jere P. Segrest, et al.
Publicado em: (2013-10-01)

Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases
Por: Anna Wolska, et al.
Publicado em: (2021-03-01)

HDL proteome and apolipoproteins concentrations in severe ICU COVID-19 patients
Por: Floran Begue, et al.
Publicado em: (2025-01-01)

Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins
Por: Shucun Qin, et al.
Publicado em: (2000-02-01)

Apolipoprotein A-I promotes cholesterol release and apolipoprotein E recruitment from THP-1 macrophage-like foam cells
Por: John K. Bielicki, et al.
Publicado em: (1999-01-01)

Identification of genetic drivers of plasma lipoprotein size in the Diversity Outbred mouse population
Por: Tara R. Price, et al.
Publicado em: (2023-12-01)

Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D
Por: Arpita Basu, et al.
Publicado em: (2018-01-01)

Metabolsim of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteininemic subjects
Por: M Berman, Ph.D., et al.
Publicado em: (1978-01-01)

Apolipoprotein A-II, a Player in Multiple Processes and Diseases
Por: Gabriela Florea, et al.
Publicado em: (2022-07-01)

Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice: effects on lipoproteins and atherosclerosis
Por: Yuko Kako, et al.
Publicado em: (1999-12-01)

Evidence for differential effects of apoE3 and apoE4 on HDL metabolism
Por: Paul C.R. Hopkins, et al.
Publicado em: (2002-11-01)